Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;9(1):349-361.
doi: 10.1007/s13300-017-0333-9. Epub 2017 Nov 14.

A Review of Insulin Resistance in Type 1 Diabetes: Is There a Place for Adjunctive Metformin?

Gagan Priya  1 , Sanjay Kalra  2
Affiliations
Review

A Review of Insulin Resistance in Type 1 Diabetes: Is There a Place for Adjunctive Metformin?

Gagan Priya et al. Diabetes Ther. 2018 Feb.

Abstract

There is a rising trend of overweight and obesity among individuals with type 1 diabetes. This is often associated with insulin resistance, increased insulin dose requirements and poor glycemic control. Insulin resistance is also seen during puberty and is strongly related to increased risk of cardiovascular disease. The role of metformin as an adjunct to ongoing intensive insulin therapy in type 1 diabetics has been evaluated in several randomized trials, including the recently concluded T1D Exchange Network trial in adolescents and the REMOVAL trial in adults. Metformin reduces the insulin dose requirement, insulin-induced weight gain, and total and LDL cholesterol, but results in an increased risk of gastrointestinal adverse effects and a minor increase in the risk of hypoglycemia. In addition, metformin has been shown to reduce maximal carotid intima media thickness and therefore may extend cardioprotective benefits in type 1 diabetes. The role of metformin as adjunctive therapy in type 1 diabetes needs to be explored further in outcome trials.

Keywords: Adjunctive therapy; Insulin resistance; Metformin; Overweight and obesity; Type 1 diabetes.

PubMed Disclaimer

References

    1. Sherr J, Tsalikian E, Fox L, et al. Dysregulation of alpha-cell function in youth during the first 2 years of T1D: recipricol abnormalities in glucagon responses to mixed meal feedings and hypoglycemia. Diabetes. 2012;61(Supplement 1):A52–A53.
    1. Livingstone R, Boyle JG, Petrie JR. Removal study team. A new perspective on metformin therapy in type 1 diabetes. Diabetologia. 2017 - PMC - PubMed
    1. Munir KM, Davis SN. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16(15):2331–2341. doi: 10.1517/14656566.2015.1084502. - DOI - PubMed
    1. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2015;22:277–282. doi: 10.1097/MED.0000000000000170. - DOI - PubMed
    1. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care. 2003;26(10):2871–2875. doi: 10.2337/diacare.26.10.2871. - DOI - PubMed

LinkOut - more resources